Relationship between 1-year change in the bone turnover marker P1NP and 3-year vertebral fracture risk reduction with raloxifene therapy in postmenopausal women with osteoporosis: Results from the MORE trial

被引：0
|
作者：
Reginster, JY
Sarkar, S
Collette, J
Zegels, B
Henrotin, Y
Bruyere, O
Wong, M
Harper, K
Agnusdei, D
机构：
[1] CHU Ctr Ville, Liege, Belgium
[2] Eli Lilly & Co, Indianapolis, IN USA
[3] Eli Lilly Italia, Florence, Italy
来源：
BONE | 2001年 / 28卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：S239 / S239
页数：1
相关论文
共 39 条
  • [21] Relationship between severity of prevalent vertebral fractures and risk of subsequent nonvertebral fractures in postmenopausal women with osteoporosis: Results from the more trial
    Delmas, PD
    Genant, H
    Crans, G
    Stock, J
    Wong, M
    Siris, E
    Adachi, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 316 - 316
  • [22] Relationship between severity of prevalent vertebral fractures and risk of subsequent nonvertebral fractures in postmenopausal women with osteoporosis: Results from the MORE trial
    Delmas, P
    Genant, H
    Crans, G
    Stock, J
    Wong, M
    Siris, E
    Adachi, J
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S38 - S39
  • [23] Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
    Junichi Takada
    Rajani Dinavahi
    Akimitsu Miyauchi
    Etsuro Hamaya
    Toshiyasu Hirama
    Cesar Libanati
    Yoichi Nakamura
    Cassandra E. Milmont
    Andreas Grauer
    Journal of Bone and Mineral Metabolism, 2020, 38 : 310 - 315
  • [24] Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
    Takada, Junichi
    Dinavahi, Rajani
    Miyauchi, Akimitsu
    Hamaya, Etsuro
    Hirama, Toshiyasu
    Libanati, Cesar
    Nakamura, Yoichi
    Milmont, Cassandra E.
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (03) : 310 - 315
  • [25] Correlations between Longitudinal Changes in the Bone Turnover Marker P1NP and Bone Formation at the Tissue Level across 3 Envelopes with Teriparatide in the AVA Osteoporosis Study.
    Dempster, David
    Zhou, Hua
    Krege, John
    Alam, Jahangir
    Taylor, Kathleen
    Ruff, Valerie
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S268 - S269
  • [26] Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
    Junichi Takada
    Rajani Dinavahi
    Akimitsu Miyauchi
    Etsuro Hamaya
    Toshiyasu Hirama
    Cesar Libanati
    Yoichi Nakamura
    Cassandra E. Milmont
    Andreas Grauer
    Journal of Bone and Mineral Metabolism, 2020, 38 : 605 - 605
  • [27] 6 months changes in biochemical markers predict 3-year response in vertebral fracture rate in postmenopausal, osteoporotic women: Results from the MORE study.
    Bjarnason, NH
    Christiansen, C
    Sarkar, S
    Mitlak, B
    Knickerbocker, R
    Delmas, P
    Cummings, S
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S157 - S157
  • [28] Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
    T. Sugimoto
    T. Matsumoto
    T. Hosoi
    T. Miki
    I. Gorai
    H. Yoshikawa
    Y. Tanaka
    S. Tanaka
    M. Fukunaga
    T. Sone
    T. Nakano
    M. Ito
    S. Matsui
    T. Yoneda
    H. Takami
    K. Watanabe
    T. Osakabe
    N. Okubo
    M. Shiraki
    T. Nakamura
    Osteoporosis International, 2015, 26 : 765 - 774
  • [29] Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
    Sugimoto, T.
    Matsumoto, T.
    Hosoi, T.
    Miki, T.
    Gorai, I.
    Yoshikawa, H.
    Tanaka, Y.
    Tanaka, S.
    Fukunaga, M.
    Sone, T.
    Nakano, T.
    Ito, M.
    Matsui, S.
    Yoneda, T.
    Takami, H.
    Watanabe, K.
    Osakabe, T.
    Okubo, N.
    Shiraki, M.
    Nakamura, T.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (02) : 765 - 774
  • [30] Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial (vol 17, pg 451, 2020)
    Takada, Junichi
    Dinavahi, Rajani
    Miyauchi, Akimitsu
    Hamaya, Etsuro
    Hirama, Toshiyasu
    Libanati, Cesar
    Nakamura, Yoichi
    Milmont, Cassandra E.
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (04) : 605 - 605
1234